Search results for "Hematologic Neoplasm"

showing 10 items of 85 documents

Diagnosis and grading of acute graft-versus-host disease in endoscopic biopsy series throughout the upper and lower intestine in patients after allog…

2019

Intestinal graft-versus-host disease (GvHD) is a potentially life-threatening condition after allogenic hematological stem cell transplantation (alloHSCT). Although efforts have been made to determine the best sites for endoscopic biopsies, an approach involving all accessible anatomical regions is lacking. We investigated 22 complete biopsy series, each comprising biopsies from 10 different sites of the upper and lower intestine from 21 patients. The majority of biopsies investigated revealed histological signs of acute GvHD. The highest incidence and most advanced grades of acute GvHD were found in the right colon and terminal ileum. We detected significant correlations between crypt or g…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentBiopsyGraft vs Host DiseaseIleumApoptosisHematopoietic stem cell transplantationDiseaseGastroenterologySeverity of Illness Index03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumansTransplantation HomologousGrading (tumors)Agedbusiness.industryStomachHematopoietic Stem Cell TransplantationEndoscopyHematologyMiddle Agedmedicine.diseaseTransplantationPatient Outcome Assessmentsurgical procedures operativemedicine.anatomical_structureGraft-versus-host diseaseOncology030220 oncology & carcinogenesisHematologic NeoplasmsFemaleStem cellbusinessImmunosuppressive Agents030215 immunologyLeukemialymphoma
researchProduct

Impact of pharmaceutical intervention on quality of life and coping strategies in patients with haematological malignancies

2015

Summary Objectives We conducted a prospective study approved by the local ethics committee to determine the impact of a pharmaceutical intervention (PI) on pain, fatigue, quality of life (QoL) and coping strategies in patients with HMs starting chemotherapy sessions. Material and methods Patients received either usual care (UC) + PI (PI group) or UC alone (UC group). They had to complete 2 questionnaires, QLQ-C30 and MAC 21, at 3 different time points: before starting the 1st chemotherapy session (T1), during the intercure (T2) and the day before starting the 2nd chemotherapy session (T3). To determine predictive factors of pain, fatigue, QoL and coping scores at T3, a multivariate ANOVA wa…

AdultMaleCoping (psychology)medicine.medical_specialtyAdolescentPharmaceutical ScienceAntineoplastic AgentsPharmacistsYoung Adult03 medical and health sciences0302 clinical medicineNursingSurveys and QuestionnairesAdaptation PsychologicalHumansMedicineIn patientProspective Studies030212 general & internal medicineProspective cohort studyReferral and ConsultationAgedAged 80 and overPharmacologybusiness.industryEthics committeeMiddle AgedhumanitiesHematologic Neoplasms030220 oncology & carcinogenesisMuscle FatigueUsual careQuality of LifePhysical therapyFemaleAnalysis of variancebusinessAnnales Pharmaceutiques Françaises
researchProduct

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical tr…

2019

BACKGROUND: The adjuvanted recombinant zoster vaccine (Shingrix) can prevent herpes zoster in older adults and autologous haemopoietic stem cell transplant recipients. We evaluated the safety and immunogenicity of this vaccine in adults with haematological malignancies receiving immunosuppressive cancer treatments. METHODS: In this phase 3, randomised, observer-blind, placebo-controlled study, done at 77 centres worldwide, we randomly assigned (1:1) patients with haematological malignancies aged 18 years and older to receive two doses of the adjuvanted recombinant zoster vaccine or placebo 1-2 months apart during or after immunosuppressive cancer treatments, and stratified participants acco…

AdultMaleHerpesvirus 3 Humanmedicine.medical_specialtyAdolescentPopulationAntineoplastic AgentsAntibodies ViralPlaceboHematological malignanciesImmunocompromised HostYoung Adult03 medical and health sciences0302 clinical medicineViral Envelope ProteinsInternal medicinemedicineHerpes Zoster VaccineHumansSingle-Blind Method030212 general & internal medicineeducationAdverse effectFatigueImmunity CellularVaccines Syntheticeducation.field_of_studyVaccinesReactogenicityH. Zosterbusiness.industryImmunogenicityMiddle AgedCD4 Lymphocyte CountInjection Site ReactionVaccinationClinical trialInfectious DiseasesHematologic Neoplasms030220 oncology & carcinogenesisH. Zoster; Vaccines; Hematological malignanciesFemaleZoster vaccinebusinessVaccinemedicine.drug
researchProduct

Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry

2009

Patients surviving invasive fungal disease (IFD) and needing further antineoplastic chemotherapy are at high risk of recurrent fungal infection. In the absence of randomised controlled trials in this area, secondary prophylactic regimens are diverse. From 448 patients registered with the Multinational Case Registry of Secondary Antifungal Prophylaxis, we performed an analysis of patients receiving caspofungin (CAS) or itraconazole (ITC). All patients had an underlying haematological malignancy and had been diagnosed with an episode of IFD earlier in their course of treatment. Data collected comprised demographics, underlying disease, first episode of IFD, antifungal prophylaxis, incidence a…

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsAdolescentItraconazoleAspergillosisChemopreventionEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundCaspofunginInternal medicinemedicineHumansAspergillosisPharmacology (medical)RegistriesMycosisAgedFirst episodebusiness.industryIncidence (epidemiology)Stem cell transplantationGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTransplantationTreatment OutcomeInfectious DiseasesMycoseschemistryHematologic NeoplasmsChemoprophylaxisFemaleAntifungal prophylaxisItraconazoleCaspofunginbusinessmedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

Caspofungin for the treatment of candidaemia in patients with haematological malignancies

2010

AbstractThis study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 × 109/L) for a median of 12 days (2–41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6–26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as …

AdultMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsNeutropeniaDrug-Related Side Effects and Adverse ReactionsCandidaemia; Caspofungin; Leukaemiamedicine.medical_treatmentAntineoplastic AgentsNeutropeniaEchinocandinsLipopeptidesYoung Adultchemistry.chemical_compoundPharmacotherapyCandidaemiaCaspofunginInternal medicinemedicineHumansLeukaemiaProspective StudiescaspofunginProspective cohort studyMycosisFungemiaAgedChemotherapyHematologybusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeInfectious DiseaseschemistryHematologic NeoplasmsleukaemiaFemaleCaspofunginbusinessFungemia
researchProduct

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis.

2013

To validate current donor selection strategies based on previous international studies, we retrospectively analyzed 2646 transplantations performed for hematologic malignancies in 28 German transplant centers. Donors and recipients were high resolution typed for HLA-A, -B, -C, -DRB1, and -DQB1. The highest mortality in overall survival analysis was seen for HLA-A, -B, and DRB1 mismatches. HLA-DQB1 mismatched cases showed a trend toward higher mortality, mostly due to HLA-DQB1 antigen disparities. HLA incompatibilities at >1 locus showed additive detrimental effects. HLA mismatching had no significant effect on relapse incidence and primary graft failure. Graft source had no impact on surviv…

AdultMaleMultivariate analysisAdolescentmedicine.medical_treatmentImmunologyGraft vs Host DiseaseHematopoietic stem cell transplantationHuman leukocyte antigenHLA-C AntigensBiochemistry03 medical and health sciencesYoung Adult0302 clinical medicineimmune system diseasesTransplantation ImmunologyGermanymedicineHLA-DQ beta-ChainsHumansAlleleSurvival rateSurvival analysis030304 developmental biologyAgedRetrospective Studies0303 health sciencesHLA-A AntigensDonor selectionbusiness.industryHistocompatibility TestingHazard ratioHematopoietic Stem Cell TransplantationCell BiologyHematologyMiddle AgedSurvival AnalysisTissue Donors3. Good healthSurvival RateHLA-B AntigensHematologic NeoplasmsHistocompatibilityImmunologyMultivariate AnalysisFemalebusiness030215 immunologyHLA-DRB1 ChainsBlood
researchProduct

Survival for patients with rare haematologic malignancies: Changes in the early 21st century

2017

Abstract Introduction Population-level survival has improved for common haematologic malignancies in the early 21st century. However, relatively few population-level data are available for rare haematologic malignancies. Methods Data were extracted from 12 cancer registries in Germany and the Surveillance, Epidemiology and End Results database in the United States (US). Cases of haematologic malignancies with an incidence of less than 1 per 100,000 were selected for analysis. Period analysis was used to determine 5-year relative survival (RS) for the years 2003–2012, and modelled period analysis was used to determine changes in survival between 2003–2007 and 2008–2012. Results Seven individ…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyPathologyTime FactorsAdolescentAnaplastic LymphomaYoung Adult03 medical and health sciencesRare Diseases0302 clinical medicineGermanyInternal medicineHumansMedicineRegistriesHealthcare DisparitiesYoung adultSurvival analysisAgedMycosis fungoidesRelative survivalbusiness.industryIncidenceIncidence (epidemiology)CancerMiddle Agedmedicine.diseaseSurvival AnalysisUnited StatesTreatment OutcomeOncologyHematologic Neoplasms030220 oncology & carcinogenesisFemaleMantle cell lymphomabusinessSEER Program030215 immunologyEuropean Journal of Cancer
researchProduct

Estimation de l’incidence des hémopathies malignes en France entre 1980 et 2012

2016

International audience; BACKGROUND:The classification of hematological malignancies (HMs) has changed in recent decades. For the first time, the French network of cancer registries (Francim) provides estimates for incidence and trends of HM in France between 1980 and 2012 for major HM subtypes.METHODS:Incidence was directly estimated by modeling the incidence rates measured in the cancer registry area. For each HM subtype, a "usable incidence period" was defined a priori, corresponding to the years for which all the registries collected them in a homogeneous way. For both sexes and each HM subtype, age-period-cohort models were used to estimate national incidence trends.RESULTS:Overall in F…

AdultMaleOncologyPediatricsmedicine.medical_specialtyRegistryAdolescentEpidemiologyChronic lymphocytic leukemiaFollicular lymphoma[SDV.CAN]Life Sciences [q-bio]/Cancer[ SDV.CAN ] Life Sciences [q-bio]/CancerHematological malignanciesYoung Adult03 medical and health sciences0302 clinical medicineNeoplasmsInternal medicinemedicineHumansRegistriesAgedAged 80 and overbusiness.industryMyelodysplastic syndromesIncidence (epidemiology)IncidencePublic Health Environmental and Occupational HealthCancer[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieHémopathies malignesMiddle AgedPlasma cell neoplasmmedicine.disease3. Good healthLymphomaCancer registryTendancesHematologic Neoplasms030220 oncology & carcinogenesisFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFranceTrendsbusinessRegistre de population030215 immunology
researchProduct

Bone marrow biopsy in hemophagocytic syndrome.

2002

Abstract Aims. Hemophagocytic syndrome (HPS) is a severe and acute clinical event occurring with fever, hepatosplenomegaly, and pancytopenia due to uncontrolled phagocytosis of blood cells and precursors. Although HPS represents a secondary phenomenon, it can mask the underlying condition, generally a neoplastic or infective disease, thus making the patient management rather difficult. The aims of this study were to point out the main pathological features useful to highlight the primary disease and show the eventual discrepancies among the different cases. Methods and results. Bone-marrow biopsies (BMBs) of 26 patients with HPS were morphologically and immunophenotypically evaluated; the p…

AdultMalePathologymedicine.medical_specialtyAdolescentHistiocytosis Non-Langerhans-CellBiopsyT-LymphocytesHepatosplenomegalyPathology and Forensic MedicineBone MarrowBiopsymedicineBiomarkers TumorHumansMolecular BiologyHistiocyteAgedAged 80 and overmedicine.diagnostic_testbusiness.industryHistiocytesCell BiologyGeneral MedicineHyperplasiaMiddle Agedmedicine.diseasePancytopeniaImmunohistochemistryHistiocytosisLeukemiaVirus DiseasesHematologic NeoplasmsHemophagocytosismedicine.symptombusinessVirchows Archiv : an international journal of pathology
researchProduct

Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.

2014

More effective treatments have become available for haematological malignancies from the early 2000s, but few large-scale population-based studies have investigated their effect on survival. Using EUROCARE data, and HAEMACARE morphological groupings, we aimed to estimate time trends in population-based survival for 11 lymphoid and myeloid malignancies in 20 European countries, by region and age.In this retrospective observational study, we included patients (aged 15 years and older) diagnosed with haematological malignancies, diagnosed up to Dec 31, 2007, and followed up to Dec 31, 2008. We used data from the 30 cancer registries (across 20 countries) that provided continuous incidence and …

AdultMalePathologymedicine.medical_specialtyAdolescentPopulationRisk AssessmentSeverity of Illness IndexDisease-Free SurvivalNOCohort StudiesYoung AdultCause of DeathConfidence IntervalsHematologic Neoplasms/diagnosis/mortality/therapyMedicineHumansRegistrieseducationSurvival analysisddc:613Cause of deathAgedRetrospective Studieseducation.field_of_studyRelative survivalbusiness.industryIncidence (epidemiology)Absolute risk reductionRetrospective cohort studyMiddle AgedCombined Modality TherapySurvival AnalysisEuropeOncologyHematologic NeoplasmsFemalebusinessDemographyCohort studyThe Lancet. Oncology
researchProduct